|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:acquisition
|
gptkb:Qualitest_Pharmaceuticals
gptkb:Par_Pharmaceutical
|
|
gptkbp:acquisition_year
|
gptkb:2014
gptkb:2016
gptkb:2017
gptkb:2018
gptkb:2020
|
|
gptkbp:ceo
|
gptkb:Dr._Blaine_Mc_Peak
|
|
gptkbp:focus
|
endocrinology
pain management
urology
|
|
gptkbp:founded
|
gptkb:1997
|
|
gptkbp:founder
|
gptkb:Dr._Carl_Icahn
|
|
gptkbp:headquarters
|
gptkb:Malvern,_Pennsylvania
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Endo Pharmaceuticals
|
|
gptkbp:industry
|
gptkb:pharmaceuticals
|
|
gptkbp:legal_issue
|
settlement agreements
bankruptcy filing
opioid litigation
|
|
gptkbp:market
|
gptkb:Europe
gptkb:North_America
|
|
gptkbp:number_of_employees
|
approximately 1,000
|
|
gptkbp:partnership
|
gptkb:Astra_Zeneca
gptkb:Pfizer
gptkb:Teva_Pharmaceuticals
Mallinckrodt Pharmaceuticals
|
|
gptkbp:philanthropy
|
gptkb:Endo_Foundation
|
|
gptkbp:product
|
gptkb:Opana_ER
gptkb:Percocet
gptkb:Vasostrict
Testosterone
|
|
gptkbp:regulatory_compliance
|
gptkb:FDA
|
|
gptkbp:research_focus
|
rare diseases
chronic pain
|
|
gptkbp:revenue
|
$1.1 billion (2020)
$1.5 billion (2018)
$2.0 billion (2013)
$1.3 billion (2019)
$1.7 billion (2016)
$1.8 billion (2015)
$1.6 billion (2017)
$1.9 billion (2014)
$2.1 billion (2012)
$2.2 billion (2011)
|
|
gptkbp:stock_symbol
|
ENDP
|
|
gptkbp:subsidiary
|
gptkb:Endo_Health_Solutions
|
|
gptkbp:type
|
gptkb:public_company
|
|
gptkbp:website
|
www.endo.com
|
|
gptkbp:bfsParent
|
gptkb:Naltrexone
|
|
gptkbp:bfsLayer
|
6
|